News & Updates

In Chinese patients with idiopathic Parkinson’s disease (IPD) on their first dopamine agonist (DA) monotherapy for >6 months, bromocriptine is associated with a lower risk of impulse control–related behavioural disorders (ICRDs) compared with pramipexole and ropinirole, an observational cohort study in Hong Kong has shown. Rotigotine demonstrated a trend towards lower ICRD risk than the latter two DAs.

Treatment with sitravatinib plus nivolumab (sitra + nivo) results in numerically longer median overall survival (OS), albeit statistically nonsignificant, in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC) compared with docetaxel, a study has shown.

Third-line treatment with sacituzumab govitecan works better than the physician’s treatment of choice in metastatic triple-negative breast cancer (mTNBC), an invasive histologic subtype with a poor prognosis and rapid progression, as shown in a recent study.